Nanobiotix Closes $100 Million Global Offering Including Full Underwriter Option Exercise

On May 26, 2026, Nanobiotix S.A. announced the closing of its global offering, which included the full exercise of the underwriters' option to purchase additional shares. The offering consisted of 2,218,467 ordinary shares (including those in the form of American Depositary Shares) and 345,099 pre-funded warrants. The transaction generated aggregate gross proceeds of approximately $100 million (approximately €86.1 million) before deducting commissions and expenses. The subscription price was set at €33.60 per ordinary share, or $38.98 per ADS. Nanobiotix intends to allocate the net proceeds primarily toward advancing its Nanoprimer and other platforms (50-60%), supporting the development of JNJ-1900 (NBTXR3) (less than 10%), and for general corporate purposes (30-40%). The company anticipates that the capital raised, combined with existing cash reserves, will provide a sufficient financial runway to fund operations into 2029. Jefferies, TD Cowen, and Stifel served as global coordinators for the offering.